Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study Meeting Abstract
| Authors: | Matulonis, U. A.; Oaknin, A.; Pignata, S.; denys, H.; Colombo, N.; Van Gorp, T.; Konner, J. A.; Romeo, M.; Harter, P.; Murphy, C. G.; Wang, J.; Method, M. W.; Esteves, B.; Coleman, R. L.; Lorusso, D. |
| Abstract Title: | Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301565 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.5512 |
| Notes: | Meeting Abstract: 5512 -- Meeting also held virtually -- Source: Wos |
